<DOC>
	<DOC>NCT01910636</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus ribavirin (RBV) in Japanese participants with chronic genotype 2 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic genotype 2 HCVinfection Male or female, age ≥ 20 years Body weight ≥ 40 kg HCV RNA ≥ 10,000 IU/mL at screening Current or prior history of clinically significant illness other than HCV Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a nonHCV etiology Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HCV genotype 2 (GT-2)</keyword>
</DOC>